

MANAGEMENT TEAM

Christopher J. Moreau
Chief Executive Officer

Dr. Christopher Bryan, PhD
Vice President Research & Operations

James Kinley, CPA, CA
Chief Financial Officer & Director

Dr. Ahmed Khalil, MD, PhD
Medical Director

BOARD OF DIRECTORS

Harry J. F. Bloomfield, KC

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD, FAMN, FRCP

Dr. Mark Williams, PhD

U.S. Ambassador (Rtd)
Howard Gutman

STOCK INFORMATION

(August 24, 2023)

Shares O/S: 15.8 Million

Market Cap: C\$ 3 Million

Recent Price: C\$.195

TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGWO

INVESTOR INQUIRIES

Christopher J. Moreau, CEO

604.398.4175

chris@algernonpharmaceuticals.com

HEAD OFFICE

Algernon Pharmaceuticals Inc.

Suite 400 - 601 West Broadway

Vancouver, BC, Canada, V5Z 4C2

CORPORATE PRESENTATION

COMPANY OVERVIEW

Algernon is a Canadian clinical stage drug development and repurposing company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for chronic cough and idiopathic pulmonary fibrosis ("IPF"), chronic kidney disease.

Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.

We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team and a globally recognized medical and scientific advisory board.



ALGERNON'S LEAD CLINICAL RESEARCH PROGRAMS

CHRONIC COUGH AND IDIOPATHIC PULMONARY FIBROSIS (IPF)

Algernon recently announced positive data showing that it met the co-primary endpoint in its Phase 2a proof of concept study evaluating NP-120 ("Ifenprodil") for the potential treatment of IPF and chronic cough. In the study, 65% of patients had stable or improved forced vital capacity ("FVC") over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%. FVC is the amount of air that can be forcibly exhaled from one's lungs after taking the deepest breath possible.

For the chronic cough part of the study's primary endpoint:

- The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks and 39.5% at 12 weeks, both with significance compared to baseline
- The geometric mean awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks with statistical significance compared to baseline

* The IPF market is expected to reach a value of USD \$3.2 B by 2025.

* The chronic cough market is expected to reach a value of USD \$9.8 B by 2027.

CHRONIC KIDNEY DISEASE (CKD)

Algernon's lead compound for the treatment and management of chronic kidney disease ("CKD") is Repirinast, an orally administered small molecule. Repirinast acts on mast cells and inhibits the release of chemical mediators by IgE-related antigen antibody interactions. Repirinast, in a unilateral ureteral obstruction mouse model of kidney fibrosis reduced fibrosis by 50% with statistical significance. Algernon has begun manufacturing a cGMP supply of the drug and is planning a phase 1 study in Q2, 2023.

* The global CKD drug market is expected to reach value of USD \$15.8 B by the end of 2024.